U
RARE icon

UBS’s Ultragenyx Pharmaceutical RARE Stock Holding History

UBS’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$28K Buy
+500
New +$25.2K ﹤0.01% 7558

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS's RARE Position: Q3 2014 in Review

UBS increased its Ultragenyx Pharmaceutical (RARE) stake by 136% in Q3 2014, buying an estimated $84.3K and bringing the position to 2,907 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #5402.

UBS first reported a position in RARE in Q2 2014 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold RARE as of Q3 2014.

  • UBS held 2,907 shares of Ultragenyx Pharmaceutical worth $165K as of Q3 2014.
  • UBS bought 1,675 Ultragenyx Pharmaceutical shares in Q3 2014, an estimated $84.3K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5402 holding.
  • UBS first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.